Torpezil (Donepezil) for Mild-to-Moderate Alzheimer's Disease
Start Torpezil at 5 mg once daily in the evening before bedtime, then increase to 10 mg daily after 4-6 weeks if tolerated. 1
Dosing Regimen
- Initial dose: 5 mg once daily in the evening, just prior to retiring
- Maintenance dose: 10 mg once daily after 4-6 weeks on the 5 mg dose
- Maximum dose for mild-to-moderate AD: 10 mg daily
- Administration: Can be taken with or without food 1
The 4-6 week titration period is critical—do not rush to 10 mg in less than 4 weeks as this significantly increases cholinergic side effects, particularly nausea and vomiting 1, 2. Studies show that gradual dose escalation reduces adverse events compared to rapid titration 2.
Contraindications
Absolute contraindication: Known hypersensitivity to donepezil or piperidine derivatives 1
Major contraindications include 3:
- Uncontrolled asthma
- Angle-closure glaucoma
- Sick sinus syndrome
- Left bundle-branch block
Critical Precautions and Warnings
Cardiovascular Effects
Monitor closely for bradycardia and heart block, even in patients without known cardiac conduction abnormalities 1. Donepezil exerts vagotonic effects on sinoatrial and atrioventricular nodes. Syncopal episodes have been reported. Studies show mean heart rate decreases of approximately 1-1.5 beats/minute 4.
Gastrointestinal Effects
Expect nausea, vomiting, and diarrhea, especially during the first 1-3 weeks after starting or increasing the dose 1. These are predictable cholinergic effects that typically resolve with continued use. However, monitor patients at increased risk for GI bleeding (history of ulcer disease, concurrent NSAID use) as cholinesterase inhibitors increase gastric acid secretion 1.
Anesthesia Risk
Donepezil will exaggerate succinylcholine-type muscle relaxation during anesthesia—inform anesthesiologists before any surgical procedure 1.
Drug Interactions
Concomitant use of cardiovascular/cerebrovascular medications significantly increases adverse event risk 4. Ketoconazole and quinidine may inhibit donepezil metabolism, though clinical significance is unclear 5.
Clinical Efficacy Considerations
The evidence shows modest but statistically significant benefits on cognition (ADAS-Cog improvement of -2.67 points, MMSE improvement of 1.05 points) and global function at 24-26 weeks 6. However, the 2008 ACP/AAFP guideline emphasizes that not all patients achieve clinically important improvements, and we cannot predict who will respond 3.
Key practice point: Assess response within 3 months 3. Look for improvement OR stabilization—either counts as a response. If the patient shows continued decline and slowing decline is no longer a goal, discontinuation is appropriate 3.
The 10 mg dose provides marginally larger benefits than 5 mg but with higher withdrawal rates (24% vs 20%) and more adverse events (72% vs 65%) 6. The recent 2025 Korean guideline strongly recommends cholinesterase inhibitors for AD based on moderate evidence for improving cognition and daily function 7.
Common Pitfalls to Avoid
- Escalating too quickly to 10 mg—wait the full 4-6 weeks to minimize cholinergic side effects
- Missing cardiac contraindications—screen for conduction abnormalities before starting
- Continuing indefinitely without reassessment—evaluate response at 3 months and discontinue if no benefit
- Ignoring drug interactions—particularly with cardiovascular medications which increase adverse event risk